Journal Article

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

Galetta, Domenico, Vincenzi, Bruno, Crinò, Lucio, Montagna, Elisabetta, Normanno, Nicola, Pinto, Carmine, Fenizia, Francesca, Ferraù, Francesco, Botti, Gerardo, Ludovini, Vienna, Lambiase, Matilde, Rachiglio, Anna, Morabito, Alessandro, Rocco, Gaetano, Barletta, Emiddio, Roma, Cristin, Montanino, Agnese, De Luca, Antonella, Piccirillo, Maria, Perrone, Francesco

2019

Overview

Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR tyrosine kinase inhibitors (TKIs). We investigated the role of concomitant KRAS, NRAS, BRAF, PIK3CA, MET and ERBB2 mutations (other mutations) on the outcome of 133 EGFR mutant patients, who received first-line therapy with EGFR TKIs between June 2008 and December 2014. Analysis of genomic DNA by Next Generation Sequencing (NGS) revealed the presence of hotspot mutations in genes other than the EGFR, including KRAS, NRAS, BRAF, ERBB2, PIK3CA, or MET, in 29/133 cases (21.8%). A p.T790M mutation was found in 9/133 tumour samples (6.8%). The progression free survival (PFS) of patients without other mutations was 11.3 months vs. 7 months in patients with other mutations (log-rank test univariate: p = 0.047). In a multivariate Cox regression model including the presence of other mutations, age, performance status, smoking status, and the presence of p.T790M mutations, the presence of other mutations was the only factor significantly associated with PFS (Hazard Ratio 1.63, 95% CI 1.04–2.58; p = 0.035). In contrast, no correlation was found between TP53 mutations and patients’ outcome. These data suggest that a subgroup of EGFR mutant tumours have concomitant driver mutations that might affect the activity of first-line EGFR TKIs.

• Publisher: MDPI AG,MDPI
• Subject: c-Met protein / DNA sequencing / Epidermal growth factor receptors / ErbB-2 protein / Genes / Genomic analysis / Lung cancer / Mutants / Mutation / Mutation hot spots / Next-generation sequencing / Non-small cell lung carcinoma / p53 Protein / Response rates / Small cell lung carcinoma / Tumors / Tyrosine kinase inhibitors